Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen EPOGEN (epoetin alfa by Year
EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — U.S. product sales ($M) ($M)
Amgen EPOGEN (epoetin alfa: $125M in FY2024, down 44.7% from a year earlier. That is the lowest of the 9 years on record here. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
“|| EPOGEN — U.S. | 125 | (45) | % | 226 | (55) | % | 506”
Source: Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — U.S. product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 125 | -44.7% | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 226 | -55.3% | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 506 | -2.9% | Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 521 | -12.9% | Form 10-K (amgn-20211231.htm, filed 2022-02-16) ↗ |
| FY2020 | Dec 31, 2020 | 598 | -31.0% | Form 10-K (amgn-20201231.htm, filed 2021-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 867 | -14.2% | Form 10-K (filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 1,010 | -7.8% | Form 10-K (filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 1,096 | -14.5% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 1,282 | – | Form 10-K (filed 2019-02-13) ↗ |
Cite this data
StockData. (2026). Amgen EPOGEN (epoetin alfa ($M), annual FY2016–FY2024 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-epogen-us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.